Vidofludimus (Vido) is a novel immunomodulatory drug that inhibits lymphocyte proliferation and interleukin (IL)-17 secretion independently. Previous work has shown that Vido effectively improves colitis in mice. However, it was not clear whether the improvement was through inhibition of leukocyte proliferation or inhibition of IL-17. The present study investigated the effects of Vido on trinitrobenzene sulfonic acid-induced colitis in young rats. In addition, coadministration of uridine was used to reverse the effects of Vido on lymphocyte proliferation. In agreement with previous mouse studies, treatment with Vido resulted in significant improvements in colitis. It is noteworthy that these improvements were still present with the coadministration of uridine but not to the same overall degree as with Vido alone. These data suggest that inhibition of both lymphocyte proliferation and IL-17 plays important roles in the effect of Vido on experimentally induced colitis in rats.
See article at J Pharmacol Exp Ther 2012, 342:850–860.
- Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics